Cite
HARVARD Citation
Chesney, J. et al. (2018). Potential clinical and immunotherapeutic utility of talimogene laherparepvec for patients with melanoma after disease progression on immune checkpoint inhibitors and BRAF inhibitors. Melanoma research. 28 (3), p. . [Online].